Nektar Therapeutics (NKTR) PT Raised to $95 at Wedbush
Wedbush analyst Martin Fan raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $95.00 (from $70.00) while maintaining a Neutral rating.
Wedbush analyst Martin Fan raised the price target on Nektar Therapeutics (NASDAQ: NKTR) to $95.00 (from $70.00) while maintaining a Neutral rating.